Related Experiment Videos
[Hyperreactive luteomas during pregnancy--symptoms and complications: a case report]
Ariane Germeyer1, Friedrich Kommoss, Thomas Strowitzki
1Abteilung für gynäkologische Endokrinologie und Reproduktionsmedizin, Universitätsfrauenklinik Heidelberg, Vossstrasse 9, Heidelberg, Germany. Ariane_Germeyer@med.uni-heidelberg.de
Gynakologisch-Geburtshilfliche Rundschau
|June 10, 2010
Summary
A pregnant woman experienced hyperandrogenic symptoms due to steroid cell hyperplasia. Surgical removal and postpartum recovery resolved the condition, highlighting a rare pregnancy complication.
Area of Science:
- Reproductive Endocrinology
- Gynecologic Oncology
- Maternal-Fetal Medicine
Background:
- Hyperandrogenic symptoms during pregnancy can indicate underlying endocrine disorders.
- Ovarian steroid cell hyperplasia is a rare condition, particularly during gestation.
- Preeclampsia poses significant risks to both mother and fetus during pregnancy.
Observation:
- A 27-year-old pregnant patient presented with escalating hyperandrogenic symptoms.
- An ovarian torsion necessitated surgical removal, revealing diffuse steroid cell hyperplasia.
- Recurrent hyperandrogenism and preeclampsia complicated the twin pregnancy.
Findings:
- Histological analysis confirmed steroid cell hyperplasia, correlating with elevated androgen levels.
- Surgical intervention provided temporary symptom relief, but hyperandrogenism recurred.
- Postpartum normalization of hormone levels and symptom resolution were observed.
Implications:
- This case underscores the importance of considering rare ovarian pathologies in pregnant patients with hyperandrogenism.
- Management requires a multidisciplinary approach involving endocrinology, gynecology, and maternal-fetal medicine specialists.
- Understanding steroid cell hyperplasia in pregnancy is crucial for accurate diagnosis and effective patient management.
Related Concept Videos
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.